25 completed, 1 active not recruiting, 1 recruiting. 15 Phase 3, 8 Phase 2, 6 Phase 1, 3 Phase 4, 2 Not applicable.
By phase and status
Follow ATV: new trials by email Literature Review of ATV trials Research Report on ATV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments F/TAF (High Dose Tablet), F/TAF (Low Dose Tablet), F/TAF (Lowest Dose Tablet) - HIV-1-infection Phase 4 Recruiting Gilead Sciences 350 2024-08-27 2026-10-19 A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions Atazanavir, Cobicistat, Atazanavir/Cobicistat Mini-tablet - Healthy Participants Phase 1 Completed Bristol-Myers Squibb 42 2022-05-13 2022-10-31 Atorvastatin Mitigates WMH-Related Cognitive Impairment by Reducing VCAM-1 Atorvastatin 10 mg daily, Placebo matching atorvastatin - Ischemic White Matter Lesions (WMIL), Cerebral Small Vessel Disease Not applicable Completed Suzhou Municipal Hospital of Anhui Province 401 2021-01-01 2025-08-17 Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet, Telmisartan 40Mg Oral Tablet, Atorvastatin 20 Mg Oral Tablet - COVID-19, COVID-19 Drug Treatment Phase 2 / Phase 3 Completed ANRS, Emerging Infectious Diseases 294 2020-11-27 2024-12-27 Comparative Evaluation Of 1.2% Atorvastatin and 1.2% Simvastatin Gel Local Drug Delivery And Redelivery In Chronic Periodontitis Subjects With Diabetes Mellitus: A Randomized Controlled Clinical Trial. ATORVASTATIN, SIMVASTATIN, PLACEBO - Chronic Periodontitis Wth Diabetes Mellitus Phase 2 / Phase 3 Completed Government Dental College and Research Institute, Bangalore 120 2017-03-03 2018-11-19 Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women E/C/F/TAF, E/C/F/TDF, ATV - HIV-1 Infection Phase 3 Completed Gilead Sciences 472 2016-02-19 2020-03-04 Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults RTV, ATV, DRV - HIV-1 Infection Phase 3 Completed Gilead Sciences 578 2015-11-20 2020-12-29 Locally Delivered Atorvastatin & Rosuvastatin for Treatment of Furcation Defects in Chronic Periodontitis placebo, Rosuvastatin, Atorvastatin - Chronic Periodontitis Phase 2 / Phase 3 Completed Government Dental College and Research Institute, Bangalore 90 2015-05-01 2016-06-15 Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults STB, TVD, ATR - HIV-1 Infection Phase 4 Completed Gilead Sciences 72 2014-12-15 2018-01-03 Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV ATV, DRV, Cobicistat - Acquired Immune Deficiency Syndrome (AIDS), HIV Infections Phase 2 / Phase 3 Active not recruiting Gilead Sciences 133 2014-01-16 2026-04-21 Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study atazanavir 300mg boosted with ritonavir 50 mg - HIV Infection Phase 1 Completed Ottawa Hospital Research Institute 12 2014-01-01 2015-09-22 Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults TAF, Placebo, E/C/F/TAF - HIV, HIV Infections Phase 3 Completed Gilead Sciences 55 2013-10-25 2018-11-16 Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF - HIV, HIV Infections Phase 3 Completed Gilead Sciences 1443 2013-03-27 2021-04-13 Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women E/C/F/TDF, ATV, RTV - Acquired Immunodeficiency Syndrome, HIV Infections Phase 3 Completed Gilead Sciences 583 2012-10-24 2019-09-20 Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients. SOF, EFV/FTC/TDF, EFV - Hepatitis C, HIV Phase 1 / Phase 2 Completed Gilead Sciences 52 2012-03-01 2014-10-01 Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment E/C/F/TDF, COBI, ATV - Acquired Immunodeficiency Syndrome, HIV Infections Phase 3 Completed Gilead Sciences 106 2011-05-01 2016-05-02 Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults Stribild, ATV, Ritonavir - HIV, HIV Infections Phase 3 Completed Gilead Sciences 708 2010-04-01 2015-11-11 Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults COBI, RTV, ATV - HIV, HIV Infections Phase 3 Completed Gilead Sciences 698 2010-04-01 2016-05-23 Comparative Study of Three NNRTI-Sparing HAART Regimens Emtricitabine/tenofovir disoproxil fumarate, Raltegravir, Darunavir - HIV Infection Phase 3 Completed Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections 1814 2009-05-01 2014-09-05 Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults COBI, RTV, ATV - HIV-1 Infection Phase 2 Completed Gilead Sciences 85 2009-05-01 2016-02-15
Showing 20 of 27. Sign in to see all of them.
Conditions studied HIV Infections (15) · Acquired Immunodeficiency Syndrome (4) · COVID-19 (1) · Cerebral Small Vessel Diseases (1) · Chronic Periodontitis (1) · Hepatitis C (1) · Tuberculosis (1)
Sponsors Gilead Sciences (13) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Bristol-Myers Squibb (2) · Government Dental College and Research Institute, Bangalore (2) · ANRS, Emerging Infectious Diseases (1) · GlaxoSmithKline (1) · Ottawa Hospital Research Institute (1) · Suzhou Municipal Hospital of Anhui Province (1)
Countries United States (19) · Puerto Rico (13) · Thailand (10) · United Kingdom (9) · Dominican Republic (8) · Belgium (7) · Canada (7) · France (7) · Australia (6) · Germany (6) · Italy (6) · Mexico (6) · Austria (5) · Portugal (5) · South Africa (5)
Top investigators Marshall Fordyce, MD (2) · Anuj Gaggar, MD/PhD (1) · Avani R Pradeep, MDS (1) · David W. Haas, MD (1) · Eric Daar, MD (1) · Huyen Cao, MD (1) · Igho Ofotokun, MD (1) · James Hakim, MscClinEpi, FRCP (1) · Javier Szwarcberg, MD (1) · Jeffrey L. Lennox, MD (1) · Jennifer King, PharmD (1) · Judith Silverstein Currier, MD, MSc (1)
Results publications PMID 24979445 , PMID 33901188 , PMID 36912172 , PMID 17576825 , PMID 19952143 , PMID 20961784 , PMID 21148235 , PMID 21320923 , PMID 21499794 , PMID 21606537 , PMID 21690627 , PMID 21732894 , PMID 21811136 , PMID 22121190 , PMID 22585772 , PMID 22748590 , PMID 22936892 , PMID 23148287 , PMID 23204164 , PMID 23337366 , PMID 23532097 , PMID 24253247 , PMID 24346640 , PMID 24384588 , PMID 24637543 , PMID 24872136 , PMID 25285539 , PMID 25397568 , PMID 25469527 , PMID 25622055 , PMID 25681380 , PMID 25767256 , PMID 25904376 , PMID 25979186 , PMID 26009829 , PMID 26181707 , PMID 26538525 , PMID 26797215 , PMID 27562742 , PMID 27715376 , PMID 27774892 , PMID 28259777 , PMID 29368537 , PMID 29925490 , PMID 30642925 , PMID 30932951 , PMID 31303140 , PMID 31430369 , PMID 31609930 , PMID 31826005
NIH funding U01AI068636 (3), 2009 (1), 2014 (1), 2015 (1), K24AI051966 (1)